Details of the Drug

General Information of Drug (ID: DMU9C8F)

Drug Name
Bavencio
Indication
Disease Entry ICD 11 Status REF
Merkel cell carcinoma 2C34 Approved [1]
Colon cancer 2B90.Z Phase 3 [2]
Gastric adenocarcinoma 2B72 Phase 3 [3]
Head and neck cancer 2D42 Phase 3 [3]
Urothelial carcinoma 2C92.0 Phase 3 [3]
Breast cancer 2C60-2C65 Phase 2 [3]
Melanoma 2C30 Phase 2 [4]
Squamous cell carcinoma 2B60-2D01 Phase 2 [3]
Testicular cancer 2C80 Phase 2 [5]
Haematological malignancy 2B33.Y Phase 1 [3]
⏷ Show the Full List of Indication(s)
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0W8HN
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Merkel cell carcinoma
ICD Disease Classification 2C34
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT03827044) Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.